Boehringer Ingelheim to Use IDBS' Predictive Modeling | GenomeWeb
NEW YORK (GenomeWeb News) – Boehringer Ingelheim researchers will use IDBS’ predictive modeling technology in its drug discovery research programs, IDBS said today.
Pharmaceutical researchers at Boehringer Ingelheim’s Biberach an der Riss facility will use IDBS’ PredictionBase “to increase efficiency of the candidate identification process,” IDBS founder and CEO Neil Kipling said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.